We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52M
AUM Growth
-$6.16B
Cap. Flow
-$249M
Cap. Flow %
-4,517.93%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
PGNY icon
Progyny
PGNY
+$22.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVS icon
101
Corvus Pharmaceuticals
CRVS
$1.12B
$6.88K 0.12%
6,943,654
– –
LUNG icon
102
Pulmonx
LUNG
$52.8M
$6.4K 0.12%
435,000
– –
SRRK icon
103
Scholar Rock
SRRK
$5.92B
$5.91K 0.11%
+1,076,540
New +$7.73M
HELP
104
Cybin Inc
HELP
$471M
$5.89K 0.11%
276,955
– –
HARP
105
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$5.8K 0.11%
303,951
– –
MIRM icon
106
Mirum Pharmaceuticals
MIRM
$6.84B
$5.44K 0.1%
279,500
+252,500
+935% +$5.96M
ELVN icon
107
Enliven Therapeutics
ELVN
$3.84B
$5.35K 0.1%
1,096,642
– –
NTRA icon
108
CALL
Natera
NTRA
$36.1B
$5.32K 0.1%
150,000
– –
IMCR icon
109
Immunocore
IMCR
$1.7B
$4.89K 0.09%
131,100
+3,000
+2% +$97.4K
CALC icon
110
CalciMedica
CALC
$11.3M
$4.54K 0.08%
297,382
– –
VOR icon
111
Vor Biopharma
VOR
$1.08B
$4.14K 0.08%
41,667
– –
BNR
112
Burning Rock Biotech
BNR
$96.9M
$4.04K 0.07%
138,980
-6,260
-4% -$280K
APLT
113
DELISTED
Applied Therapeutics
APLT
$4.03K 0.07%
+4,250,000
New +$6.96M
ACHL
114
DELISTED
Achilles Therapeutics
ACHL
$3.99K 0.07%
1,584,845
– –
CTMX icon
115
CytomX Therapeutics
CTMX
$701M
$3.89K 0.07%
2,124,975
– –
NVAX icon
116
CALL
Novavax
NVAX
$1.21B
$3.86K 0.07%
+75,000
New +$3.88M
CLDX icon
117
Celldex Therapeutics
CLDX
$2.79B
$3.04K 0.06%
112,700
-293,400
-72% -$8.52M
LOGC
118
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2.97K 0.05%
8,466,783
– –
AFIB
119
DELISTED
Acutus Medical Inc
AFIB
$2.97K 0.05%
2,648,386
– –
DNTH icon
120
Dianthus Therapeutics
DNTH
$5.55B
$2.7K 0.05%
140,685
– –
ABCL icon
121
CALL
AbCellera Biologics
ABCL
$1.62B
$2.66K 0.05%
+250,000
New +$2.12M
IMDX
122
Insight Molecular Diagnostics
IMDX
$149M
$2.55K 0.05%
141,890
-32,800
-19% -$746K
TARA icon
123
Protara Therapeutics
TARA
$221M
$2.43K 0.04%
830,641
– –
LENZ
124
LENZ Therapeutics
LENZ
$184M
$2.33K 0.04%
121,202
-102,485
-46% -$2.28M
NMTR
125
DELISTED
9 Meters Biopharma
NMTR
$2.22K 0.04%
425,286
-88,508
-17% -$834K
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52M, down 100% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $249M in Q2 2022, closing 15 positions and reducing 36 holdings. Its most notable exit was DexCom, an estimated $76.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Progyny worth $18.2K.

  • OrbiMed's largest Q2 2022 buy was Progyny: 625,000 shares worth $18.2K.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52M portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 100% quarter-over-quarter to $5.52M.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.